MXCT Live signals | Maximize Profits with Getagraph.com

BUY 125084 min ago

@ $4.78

Issued: 14 Feb 2024 @ 12:00

Return: -0.84%

Previous signal: Feb 13 - 10:49

Previous signal: Sell

Return: -0.46 %

Live Chart Being Loaded With Signals

Commentary (10 May 2024 @ 16:00):

Stats
Today's Volume	354 526
Average Volume	596 191
Market Cap	495.42M
EPS	$0 ( 2024-05-08 )
Next earnings date	( $0 ) 2024-08-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-12.81
ATR14	$0.00700 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-26	Johnston John Joseph	Buy	5 000	Common Stock
2024-03-26	Johnston John Joseph	Sell	5 000	Common Stock
2024-03-26	Johnston John Joseph	Sell	5 000	Stock Option (right to buy)
2024-03-15	Ross Thomas M.	Buy	100 000	Employee Stock Option (right to buy)
2024-03-15	Ross Thomas M.	Buy	25 000	Common Stock

INSIDER POWER
40.25
Last 100 transactions
Buy: 1 609 082 \| Sell: 743 053

Volume Correlation

Long: 0.25 (neutral)

Short: 0.71 (moderate)

Signal:(60.118) Neutral

MaxCyte, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

MaxCyte, Inc. Correlation - Currency/Commodity

-0.70
( moderate negative )

-0.54
( weak negative )

0.00
( neutral )

0.32
( neutral )

0.00
( neutral )

0.41
( neutral )

MaxCyte, Inc. Financials

Annual	2023
Revenue:	$41.29M
Gross Profit:	$32.56M (78.86 %)
EPS:	$-0.370

FY	2023
Revenue:	$41.29M
Gross Profit:	$32.56M (78.86 %)
EPS:	$-0.370

FY	2022
Revenue:	$44.26M
Gross Profit:	$39.16M (88.48 %)
EPS:	$-0.190

FY	2021
Revenue:	$33.89M
Gross Profit:	$30.25M (89.24 %)
EPS:	$-0.210

Financial Reports:

No articles found.

MaxCyte, Inc.

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.